NCCN Updates in Bile Duct Cancer Put Focus on Precision Medicine
The addition of immunotherapy and targeted therapies to the NCCN guidelines in bile duct cancer means that tumor mutation profiling is now called for to guide treatment decisions.
Pemigatinib: EMA Panel Offers Conditional Nod for Pemigatinib
The EMA panel's nod pemigatinib in bile duct cancer is the latest positive news for the targeted therapy after its FDA approval and appearance in the NCCN Guidelines.
Dr Al B. Benson Discusses Ongoing Work That Could Affect Future NCCN Guidelines
Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.
Dr Michael D’Angelica on the Importance of NCCN Guideline Updates and Progress in Hepatobiliary Cancer
Michael I. D'Angelica, MD, FACS, director of the Hepatopancreatobiliary Fellowship Program at Memorial Sloan Kettering Cancer Center, discusses the NCCN guidelines for hepatobiliary cancers.
2 Clarke Drive Cranbury, NJ 08512